Affordable Prescriptions for Patients Act

This bill puts limits on how many patents the maker of a biologic drug can use in a lawsuit against a company trying to sell a cheaper, similar version of that drug. There is already a system that gives these competing companies a shorter path to getting approved by the FDA, and this bill adds new rules within that system. If the company making the similar version follows certain steps, like sharing product information with the original drugmaker, then the original drugmaker can only use a limited number of certain patents in court, especially patents that were filed more than four years after the original drug was approved for sale. However, a judge can allow more patents to be used if fairness requires it.

Your Vote